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Abstract  
BACKGROUND: Ovarian cancer is considered the most lethal of all gynecological malignancies 
and ranks fifth among the most common cause of cancer deaths in women (1). There is 
evidence that the site of origin for the majority of the most serious form of ovarian cancers, 
high-grade serous carcinoma (HGSC), is the fallopian tube (4). Further evidence from the 
Sectioning and Extensively Examining the FIMbria (SEE-FIM) protocol revealed tubal 
involvement as well as serous intraepithelial carcinomas in 70% and 40-60% of unselected 
women diagnosed with ovarian or primary peritoneal HGSC respectively (8-14). As a result, 
there has been growing consensus as to whether risk-reducing salpingectomies (RRS) should be 
performed for women who are at moderate risk for developing ovarian cancer especially at a 
time of patient desired sterilization. A retrospective chart review and review of the literature to 
determine the safety and cost of risk-reducing salpingectomies performed as sterilizations in 
comparison to tubal ligations was performed using the Healthcare Cost and Utilization Project 
inpatient database from 2008-2012.  
METHODS: Safety was assessed by examining ICD-9 codes associated with unintentional 
intraoperative injuries and length of hospital stay between bilateral salpingectomy without 
oophorectomy and tubal ligation. Women older than 50 yrs., with a family history of ovarian 
cancer, BRCA positive, a lack of menstrual activity in the past 12 months, and imaging 
suggestive of ovarian cyst or tubal pathology at transvaginal ultrasound were excluded. Cost 
was determined and compared between the two procedures through the total charges listed 
with each procedure. Data for length of hospital stay, total charges, and unintentional 
intraoperative injury were analyzed using multiple linear regression models to calculate 
coefficients (95%CI), p-values, and odds ratios. These were adjusted for age, gender, race, 
Charlson score, admission type, median income, primary payer, and selected hospital 
characteristics (size, teaching vs non-teaching, location/region). All estimates were adjusted 
using the population weights provided by HCUP.  
  
 
 
RESULTS: There was no significant difference in the length of hospital stay between each of the 
procedures with the bilateral salpingectomy procedure having a mean stay of 0.29 days greater 
than tubal ligation (95%CI -0.19, 0.79 p: 0.24). There was no significant difference between 
intraoperative injuries when comparing bilateral salpingectomy to tubal ligation with an odds 
ratio of 4.84 (95%CI 0.38, 60.9 p: 0.22). There was a significant difference between the total 
charges associated with each procedure with tubal ligation having a mean cost of $2,227.21 
(95%CI $403.2, $4051.10) and the bilateral salpingectomy procedure having a mean cost of 
$11,189.80 (95%CI $6,582.70, $15,796.80 p<0.001).  
CONCLUSIONS:  According to this study and literature review the safety of both bilateral 
salpingectomy without oophorectomy and tubal appears to be comparable. The large cost 
difference between the two procedures should shift the conversation towards the question of 
whether hospital billing and insurance coverage for bilateral salpingectomy without 
oophorectomy should be examined more closely in order to provide RRS as a prophylactic 
treatment for women at moderate risk for developing ovarian cancer seeking sterilization.  
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Introduction  
Ovarian cancer is considered the most lethal of all gynecological malignancies and ranks fifth 
among the most common cause of cancer deaths in women. Even with improvements in 
surgical and adjuvant treatment for ovarian cancer, the prognosis remains poor with a five-year 
survival rate of only 45% (1).  
The histological subtypes of ovarian cancer that present with the morphological classification of 
being epithelial ovarian carcinomas (EOCs) include: high-grade serious carcinoma (HGSC), clear 
cell carcinoma (CCC), endometrioid carcinoma (EC), mucinous carcinoma, and low-grade serous 
carcinoma. Of all these subtypes, seventy percent of EOCs possess HGSC histology (2). These 
serous tumors are considered quite aggressive with many being detected in the more advanced 
stages and commonly reoccur despite platinum-based and surgical treatments (3).   
There is evidence that the site of origin for the majority of these HGSCs is the fallopian tube (4). 
This was determined primarily in a study where women who carried BRCA1/2 mutations that 
underwent prophylactic salpingo-oophorectomies had most of the serous intraepithelial 
carcinomas (STICs) arising from the fimbrial ends of the fallopian tube (5-7). This finding led to 
the development of the Sectioning and Extensively Examining the FIMbria (SEE-FIM) protocol 
which subsequently revealed tubal involvement as well as STICs in 70% and 40-60% of 
unselected women diagnosed with ovarian or primary peritoneal HGSC respectively (8-14).  
Current State of Prophylactic Treatment for Ovarian Cancer 
Prophylactic bilateral salpingo-oophorectomies (BSO) have been indicated for women that are 
BRCA1/2 carriers and has even been suggested for women at moderate risk of developing 
ovarian cancer. However, there are some long-term complications to consider with this form of 
prophylactic treatment.  
Over 600,000 hysterectomies are performed each year in the United States with about 55% 
accompanied by BSO (15). A large analysis of over 20,000 patients by the Nurses’ Health Study 
revealed that all-cause mortality, as well as cancer mortality, increased with women who 
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received BSO (16). This increase in mortality was primarily due to increases in heart disease and 
stroke among those patients; furthermore, it was concluded that with an expected lifespan of 
35 years after surgery, there will be one early death for every nine BSOs performed (16).   
The risks associated with BSO at the time of hysterectomy has begun shifting the consensus 
towards leaving the ovaries in place for prolonged hormone exposure and instead focusing on 
the removal of the fallopian tubes.  
Shifting Consensus towards Risk-Reducing Salpingectomy as Prophylactic Treatment of Ovarian 
Cancer 
In 2000, a review of US health care statistics stated that approximately 700,000 bilateral tubal 
sterilizations (BTS) were performed annually with 11 million US women 15 to 44 years of age 
relying on tubal sterilization as a form of contraception (17). Instead of performing tubal 
ligations, consideration should be given to risk-reducing salpingectomies (RRS) for women 
seeking permanent sterilization.  
In addition, RRS should be considered as an optional procedure during other open or 
laparoscopic surgeries, such as cesarean births, for women who are at average risk of 
developing ovarian cancer. This would be more feasible in comparison to a laparoscopic RRS 
being performed for the sole purpose of reducing the risk of pelvic serous carcinoma as only 
11.6 per 100,000 women a year with average risk end up with ovarian cancer (18).  
Essentially, this retrospective study and review of literature will hope to answer the question of 
whether risk-reducing salpingectomy compared to laparoscopic tubal ligation is safe as a form 
of sterilization and prophylactic treatment.  
Current Data 
The Efficacy of Risk-Reducing Salpingectomy 
A population-based cohort study out of Stockholm, Sweden compared data on women with 
previous surgery on benign indication (sterilization, salpingectomy, hysterectomy, and BSO) to 
women who were unexposed to any treatment between the years 1973 and 2009. They 
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discovered a statistically significant lower risk for ovarian cancer among women with previous 
salpingectomy when compared with the unexposed population. In addition, risk reductions 
were also found among women with previous hysterectomy, sterilization, and hysterectomy 
with BSO. In comparison to unilateral salpingectomy, bilateral salpingectomy was associated 
with a 50% decrease in the risk of ovarian cancer.  They concluded that the removal of the 
fallopian tubes by itself, or concomitantly with other benign surgery, is an effective way to 
reduce the risk of ovarian cancer in the general population. (19) 
The Safety of Risk-Reducing Salpingectomy  
There are existing studies discussing the safety and projected costs of risk-reducing 
salpingectomies. In a particular study conducted in Valencia, Spain by Minig et al., 97 
premenopausal women who had undergone hysterectomy plus bilateral salpingectomy were 
compared with 71 premenopausal women who received simple hysterectomies. The study 
found that with regards to the average operative time, estimated blood loss, uterine size, and 
intraoperative complications, results were similar between the two groups. In addition, there 
were no significant differences reported between the groups in terms of emergency visits after 
readmission and hospital readmission.  (20) 
Ovarian Preservation after Risk-Reducing Salpingectomy 
Another study conducted by Morelli et al. examined operative time, variation in hemoglobin 
levels, postoperative hospital stays, postoperative return to normal activity, and complication 
rates between two groups of 79 women who underwent total laparoscopic hysterectomy (TLH) 
plus bilateral salpingectomy and standard TLH without salpingectomy, respectively. It was 
determined that there were no significant differences between these groups. It was also 
determined that there were no negative effects on ovarian function in the group with TLH plus 
bilateral salpingectomy as measured by changes in FSH, Antral Follicle Count, AMH, and mean 
ovarian diameters in comparison to the TLH without salpingectomy group. (21) 
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The Estimated Cost of Risk-Reducing Salpingectomy 
With regards to cost, one study constructed a Markov Monte Carlo simulation model to 
estimate the costs and benefits of opportunistic salpingectomy in a hypothetical cohort of 
women. They estimated that salpingectomy for surgical sterilization was more costly ($9,719.52 
+- 3.74) than tubal ligation ($9,339.48 + 26.74) but more effective of reducing the risk of 
ovarian cancer by 29.2% and increasing life expectancy. (22) 
Patient Perception of Risk-Reducing Salpingectomy  
The perception of RRS from a patient's perspective is vital in addressing their concerns about 
the procedure as well as encouraging them to have it performed if they seek sterilization. One 
study performed a questionnaire of 100 healthy female volunteers regarding their medical 
history, demographics, and thoughts on RRS. Among those respondents, 71% were unaware of 
the seriousness of ovarian cancer, 79% were unaware the fallopian tube is indicated as the 
origin of HGSCs and 87% stated they never heard of RRS as a form of prophylactic treatment for 
ovarian cancer. Of these respondents, 98% agreed that they had the right to be informed about 
RRS as well as the choice to undergo the procedure. However, 68% reported fears regarding the 
potential risk of surgical complications while 3% reported fears regarding the surgical cost of 
the procedure. (23)  
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Methods   
Data Collection 
Available data found in the Healthcare Cost and Utilization Project nationwide inpatient 
database on patients who received ICD-9 procedure codes related to the procedures as listed 
below will be collected from January 1, 2008 through December 31, 2012.  
Population Exclusion Criteria  
Exclusion: Women older than 50 yrs., with a family history of ovarian cancer, BRCA positive, a 
lack of menstrual activity in the past 12 months, and imaging suggestive of ovarian cyst or tubal 
pathology at transvaginal ultrasound will be excluded.  
Statistical Analysis  
Data for length of hospital stay, total charges, and unintentional intraoperative injury were 
analyzed using multiple linear regression models to calculate coefficients with 95% confidence 
intervals, p-values, and odds ratios. These were adjusted for age, gender, race, Charlson score, 
admission type, median income, primary payer, and selected hospital characteristics (size, 
teaching vs non-teaching, location/region). All estimates were adjusted using the population 
weights provided by HCUP.  
 
  
6 
 
Table 1. ICD-9 Procedure Codes  
Tubal Ligation Procedures - Occlusion ICD-9-CM  
Occlusion of Bilateral Fallopian Tubes via Percutaneous Endoscopic 
Approach  66.21, 66.22, 66.29  
Tubal Ligation Procedures – Destruction  ICD-9-CM 
Destruction of Bilateral Fallopian Tubes via Percutaneous Endoscopic 
Approach  66.29 
Bilateral Salpingectomy Procedures ICD-9-CM 
Resection of Bilateral Fallopian Tubes via Percutaneous Endoscopic 
Approach  66.51 
Resection of Bilateral Fallopian Tubes via Natural or Artificial Opening  66.51 
Resection of Bilateral Fallopian Tubes via Natural or Artificial Endoscopic 66.51 
Resection of Bilateral Fallopian Tubes via Natural or Artificial Opening 
with Percutaneous Endoscopic Assistance  66.51 
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Table 2. ICD-9 Intraoperative Injury Codes 
Unintentional Intraoperative Injury Descriptor ICD-9-CM 
Accidental cut, puncture, perforation, or hemorrhage during surgical 
operation E8700 
Removal of other organ (partial) (total) causing abnormal patient 
reaction, or later complication, without mention of misadventure at 
time of operation 
E8786 
Other specified surgical operations and procedures causing abnormal 
patient reaction, or later complication, without mention at time of 
operation 
E8788 
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Results 
Table 3. Demographics and Hospital Characteristics 
 
Occlusion of Bilateral 
Fallopian Tubes via 
Percutaneous 
Endoscopic Approach 
 
ICD-9:  66.22. 
N=4,332 
Destruction of Bilateral 
Fallopian Tubes via 
Percutaneous 
Endoscopic Approach 
 
ICD-9:  66.29 
N=5,503 
Resection of Bilateral 
Fallopian Tubes via 
Percutaneous, Natural, 
or Artificial Opening 
with Endoscopic 
Approach or 
Percutaneous 
Endoscopic Assistance 
 
ICD-9:  66.51 
N=1,986 
P-value 
Age, years 
(mean, 95% CI) 
30.6 (32.3, 30.9) 30.9 (30.5, 31.2) 37.4 (36.7, 38.2) <0.001 
Race (%, 95% CI) 
Caucasian 
African American 
Hispanic 
Others 
 
41.9 (38.5, 45.4) 
14.4 (14.1, 17.1) 
34.8 (31.5, 38.2) 
8.8 (7.0, 11.1) 
 
54.4 (51.2, 57.6) 
16.6 (14.4, 19.1) 
20.8 (18.4, 23.5) 
8.1 (6.5, 10.0) 
 
55.2 (49.9, 60.3) 
20.8 (16.9, 25.4) 
17.6 (13.9, 21.9) 
6.4 (4.2, 9.5) 
<0.001 
Charlson Score for 
Comorbidities  
(%, 95% CI) 
0 
1 
>=2 
 
 
 
95.3 (93.6, 96.5) 
4.2 (3.0, 5.8) 
0.46 (0.17, 1.3) 
 
 
 
93.2 (91.4, 94.5) 
5.9 (4.7, 7.5) 
0.89 (0.47, 1.6) 
 
 
 
85.1 (81.3, 88.3) 
13.8 (10.8, 17.6) 
1.0 (0.37, 2.7) 
<0.001 
Admission Type  
(%, 95% CI) 
Non-Elective 
Elective 
 
72.9 (69.8, 75.7) 
27.1 (24.3, 30.2) 
 
65.9 (63.2, 68.7) 
34.0 (31.3, 36.8) 
 
46.4 (41.5, 51.4) 
53.6 (48.6, 58.5) 
<0.001 
Median Income 
(%, 95% CI) 
1st Quartile 
2nd Quartile 
3rd Quartile 
4th Quartile 
 
38.2 (34.7, 41.9) 
29.9 (26.6, 33.5) 
20.9 (18.0, 24.1) 
10.9 (8.7, 13.5) 
 
37.8 (34.7, 41.1) 
30.7 (27.7, 33.4) 
18.6 (16.1, 21.3) 
12.8 (10.8, 15.2) 
 
29.4 (24.8, 34.5) 
21.1 (17.2, 25.8) 
27.3 (22.3, 32.3) 
22.1 (17.9, 26.9) 
<0.001 
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Primary Payer  
(%, 95% CI) 
Medicare 
Medicaid 
Private uninsured 
Self-Pay/Others 
 
1.2 (0.69, 2.4) 
66.6 (63.2, 69.9) 
25.0 (22.2, 28.3) 
7.0 (5.4, 9.1) 
 
1.2 (0.13, 2.3) 
49.7 (46.6, 52.9) 
42.7 (39.5, 45.8) 
6.3 (4.9, 8.0) 
 
3.4 (1.9, 5.9) 
21.4 (17.5, 26.0) 
62.9 (57.8, 67.8) 
12.1 (9.2, 16.0) 
<0.001 
Hospital Bed Size (%, 
95% CI) 
Small 
Medium 
Large 
 
14.9 (12.6, 17.4) 
27.3 (24.4, 30.3) 
57.8 (54.4, 61.1) 
 
22.8 (20.4, 25.3) 
24.2 (21.7, 26.8) 
53.1 (50.1, 56.0) 
 
8.9 (6.4, 12.0) 
20.2 (16.5, 24.5) 
70.9 (66.2, 75.1) 
<0.001 
Hospital location (%, 
95% CI) 
Rural 
Urban 
 
17.9 (15.3, 20.9) 
82.0 (79.1, 84.7) 
 
22.3 (19.8, 25.1) 
77.7 (74.9, 80.2) 
 
12.3 (9.3, 16.2) 
87.6 (83.8, 90.7) 
<0.001 
Hospital Region  
(%, 95% CI) 
Northwest 
Midwest 
South 
West 
 
8.8 (7.0, 10.9) 
13.2 (11.0, 15.6) 
47.7 (44.4, 51.0) 
30.3 (27.3, 33.5) 
 
11.3 (9.6, 13.4) 
28.3 (25.7, 30.9) 
43.3 (40.4, 46.3) 
17.1 (14.9, 19.4) 
 
24.7 (20.7, 29.2) 
16.2 (12.8, 20.1) 
40.5 (35.8, 45.5) 
18.5 (14.9, 22.7) 
<0.001 
Hospital Teaching 
Status (%, 95% CI) 
Non-Teaching 
Teaching 
 
50.4 (46.8, 53.9) 
49.6 (46.0, 53.2) 
 
60.1 (56.9, 63.2) 
39.9 (36.8, 43.0) 
 
52.8 (47.6, 58.0) 
47.1 (41.9, 52.4) 
<0.001 
Year (%, 95% CI) 
2008 
2009 
2010 
2011 
2012 
 
27.1 (24.3, 30.2) 
25.2 (22.4, 28.2) 
16.9 (14.6, 19.6) 
18.6 (16.1, 21.3) 
12.1 (10.1, 14.5) 
 
29.0 (26.4, 31.8) 
20.5 (18.2, 23.0) 
18.1 (15.9, 20.4) 
18.3 (16.1, 20.7) 
14.1 (12.1, 16.3) 
 
15.0 (11.9, 18.8) 
8.7 (6.3, 11.9) 
56.8 (51.8, 64.7) 
10.0 (7.5, 13.5) 
9.3 (6.8, 12.6) 
<0.001 
All P-values were calculated using Linear regression for continuous variable and Chi-Squared analysis for categorical variables 
after implementing population weights.  Estimates does not consider missing data. This table highlights the demographics of 
each population that fell within their respective surgical procedure categories. Major highlights from this set emphasize 
Caucasians, individuals without comorbidities, and 1st quartile income earners as the typical patients to receive the listed 
sterilization procedures. Medicaid patients received the most sterilization procedures for tubal ligation while self-pay was done 
with salpingectomy. Most procedures were done non-electively in the year 2010.  
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Table 4. Assessing the Association between Procedure, Length of Stay and Total Charges 
Respectively 
Predictors Coefficient (95% CI) P-Value1 
   
Length of Stay    
   
Procedure 
ICD 9: 66.22 
ICD 9: 66.29 
ICD 9: 66.51 
 
REF 
-0.09 (-0.42, 0.24) 
0.29 (-0.19, 0.79) 
 
 
0.58 
0.24 
   
Total Charges (Cost)    
   
Procedure 
ICD 9: 66.22 
ICD 9: 66.29 
ICD 9: 66.51 
 
REF 
2,227.21 (403.2, 4,051.1) 
11,189.8 (6,582.7, 15,796.8) 
 
 
0.01 
<0.001 
   
1Coefficients (95%CI) and p-values were calculated using multiple linear regression adjusting for age, gender, race, Charlson 
score, admission type, median income, primary payer, and selected hospital characteristics (size, teaching vs non-teaching, 
location/region).  All Estimates were adjusted using the population weights provided by HCUP. This table highlights that 
between women who received either tubal ligation or salpingectomy there was no significant difference in length of hospital 
stay but a significant cost difference between the two with salpingectomies typically costing much more.  
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Table 5. Unintentional Intraoperative Complications by Procedure 
Predictors OR (95% CI) P-Value1 
E-Code 8700    
   
Procedure 
ICD 9: 66.22 
ICD 9: 66.29 
ICD 9: 66.51 
 
REF 
9.21 (0.87, 96.9) 
4.84 (0.38, 60.9) 
 
 
0.06 
0.22 
   
E-CODE 8786   
   
Procedure 
ICD 9: 66.22 
ICD 9: 66.29 
ICD 9: 66.51 
 
REF 
0.89 (0.14, 5.56) 
1.41 (0.04, 47.2) 
 
 
0.90 
0.84 
   
E-CODE 8788   
   
Procedure 
ICD 9: 66.22 
ICD 9: 66.29 
ICD 9: 66.51 
 
REF 
3.04 (0.57, 16.1) 
4.17 (0.55, 31.5) 
 
 
0.19 
0.16 
   
1Odds Ratios (95%CI) and p-values were calculated using multiple logistic regression adjusting for age, gender, race, Charlson 
score, admission type, median income, primary payer, and selected hospital characteristics (size, teaching vs non-teaching, 
location/region).  All Estimates were adjusted using the population weights provided by HCUP. This table highlights that there 
was no significant difference between either tubal ligation or salpingectomy for accidental intraoperative injuries as provided 
by the different ICD-9 accidental injury codes. 
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Table 6. Association between Population, Hospital Characteristics, LOS and Total Charges, 
respectively  
Demographics and Hospital 
Characteristics Length of Stay  Total Cost  
 Coefficient (95% CI) P-value Coefficient (95% CI) P-value 
Age, years  
(Per 10-year Increase) 0.015 (-0.19, 0.22) 0.88 
1903.5  
(426.8, 3380.1) 0.01 
Race  
Caucasian 
African American 
 
Hispanic 
 
Others 
 
REF 
0.57 (0.04, 1.10) 
 
0.05 (-0.23, 0.34) 
 
-0.01 (-0.28, 0.26) 
 
 
0.03 
 
0.74 
 
0.92 
 
REF 
3157.1  
(-37.5, 6351.7) 
1369.6 
(-725.0, 3464.2) 
1612.7 
(-1894.8, 5120.3) 
 
 
0.05 
 
0.20 
 
0.36 
Charlson Score for 
Comorbidities  
0 
1 
 
>=2 
 
 
REF 
0.25 (-0.33, 0.83) 
 
3.46 (-1.05, 7.98) 
 
 
 
0.40 
 
0.13 
 
 
REF 
1364.2  
(-3790.0, 6518.5) 
30625.7 
(6878.4, 54372.9) 
 
 
 
0.60 
 
0.01 
Admission Type  
Non-Elective 
Elective 
 
REF 
-0.25 (-0.39, -0.11) 
 
 
0.001 
 
REF 
-632.2 
(-1556.6, 292.0) 
 
 
0.18 
Median Income  
1st Quartile 
2nd Quartile 
 
3rd Quartile 
 
4th Quartile 
 
REF 
-0.07 (-0.36, 0.22) 
 
0.06 (-0.41, 0.52) 
 
0.006 (-0.35, 0.36) 
 
 
0.62 
 
0.81 
 
0.97 
 
REF 
-162.5   
(-2293.1, 1968.0) 
1623.3 
(-892.6, 4139.4) 
29.5 
(-2922.4, 2981.6) 
 
 
0.88 
 
0.20 
 
0.98 
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Primary Payer  
Medicare 
Medicaid 
 
Private uninsured 
 
Self-Pay/Others 
 
REF 
-0.47 (-1.85, 0.91) 
 
-0.77 (-2.12, 0.57) 
 
-0.06 (-1.65, 1.52) 
 
 
0.50 
 
0.26 
 
0.93 
 
REF 
1782.4  
(-3523.1, 7087.9) 
4022.5 
(-1161.3, 9206.3) 
4038.9 
(-2783.3, 10861.2) 
 
 
0.51 
 
0.12 
 
0.24 
Hospital Bed Size  
Small 
Medium 
 
Large 
 
REF 
-0.08 (-0.63, 0.46) 
 
-0.22 (-0.75, 0.31) 
 
 
0.76 
 
0.41 
 
 
REF 
-775.4 
(-3594.7, 2043.9) 
-959.3 
(-3735.7, 1816.9) 
 
 
0.58 
 
0.49 
Hospital location  
Rural 
Urban 
 
REF 
-0.006 (-0.23, 0.23) 
 
 
0.95 
 
REF 
4669.8 (2421.9, 6917.7) 
 
 
<0.001 
Hospital Region  
Northwest 
Midwest 
 
South 
 
West 
 
REF 
0.05 (-0.32, 0.43) 
 
0.20 (-0.11, 0.52) 
 
-0.03 (-0.35, 0.29) 
 
 
0.77 
 
0.21 
 
0.85 
 
REF 
-2583.3  
(-6002.3, 835.5) 
-1382.6 
(-4805.7, 2040.5) 
7956.2  
(4105.7, 11806.6) 
 
 
0.13 
 
0.42 
 
<0.001 
Hospital Teaching Status  
Non-Teaching 
Teaching 
 
REF 
0.33 (0.07, 0.59) 
 
 
0.01 
 
REF 
-2754.5  
(-4521.2, -987.7) 
 
 
0.002 
Year  
2008 
2009 
 
2010 
2011 
2012 
 
REF 
-0.03 (-0.42, 0.36) 
 
0.05 (-0.21, 0.31) 
N/A 
N/A 
 
 
0.88 
 
0.69 
 
REF 
581.5 
(-1699.9, 2863.0) 
N/A 
N/A 
N/A 
 
 
0.61 
Coefficients (95% CI) and p-values calculated using multiple linear regression adjusting for all other predictors in the model. All 
estimates were adjusted using the population weights provided by HCUP. This table highlights that the length of stay and cost 
were not significantly different depending on the demographics of the patients who received either tubal ligations or 
salpingectomies. The statistical differences do show that the length of stay is less for patients who received sterilization through 
an elective procedure and longer for places that were teaching hospitals. Cost was statistically different for hospitals that were 
in the West (more expensive), were teaching (less expensive), and had greater than two comorbidities (more expensive).   
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Data Analysis Summary  
There was no significant difference in the length of hospital stay between each of the 
procedures with the bilateral salpingectomy procedure having a mean stay of 0.29 days greater 
than tubal ligation (95%CI -0.19, 0.79 p: 0.24). There was no significant difference between 
intraoperative injuries when comparing bilateral salpingectomy to tubal ligation with an odds 
ratio of 4.84 (95%CI 0.38, 60.9 p: 0.22). There was a significant difference between the total 
charges associated with each procedure with tubal ligation having a mean cost of $2,227.21 
(95%CI $403.2, $4051.10) and the bilateral salpingectomy procedure having a mean cost of 
$11,189.80 (95%CI $6,582.70, $15,796.80 p<0.001). 
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Discussion  
As indicated by the above results, the safety of both bilateral salpingectomy without 
oophorectomy and tubal ligation with regards to the length of hospital stay and unintentional 
intraoperative injury appears to be comparable. The results of this analysis appear to agree and 
augment the rising argument that risk-reducing salpingectomies are considered safe 
procedures and comparable to tubal ligations when examining short-term outcomes such as 
operation time, intraoperative blood loss, length of stay, and intraoperative 
complications/injuries (20). With this in mind, physicians can be assured when they encourage 
their patients, who are considering tubal ligation for desired sterilization, to pursue bilateral 
salpingectomy as a possibility for not only its safety but for its ability to reduce the risk for 
ovarian cancer.  
Despite the relatively new concept of risk-reducing salpingectomies and need for further 
prospective cohort studies to concretely determine its efficacy in risk-reduction, the studies 
discussed below are just a few of the growing number of cases that support the idea that 
salpingectomies can reduce the risk of ovarian cancer. 
As previously mentioned, in a population-based cohort study by Falconer et al., it was 
determined that the risk for ovarian cancer among women who underwent salpingectomy were 
considerably lower when compared with the unexposed population (hazard ratio = 0.65, 95%CI 
0.52-0.81). They also discovered that bilateral salpingectomy demonstrated better outcomes 
when comparing the incidence of ovarian cancer than unilateral salpingectomy (bilateral HR = 
0.35, 95%CI = 0.17-0.73 and unilateral HR = 0.71, 95%CI = 0.56-0.91). (19) 
Another study conducted by Dilly et al., used Monte-Carlo simulations estimating ovarian 
cancer risk reduction, complication rates, utilities and associated costs obtained from already 
published literature regarding opportunistic/risk-reducing salpingectomy while assessing 
incremental cost-effectiveness ratios (ICER) and quality adjusted life years (QALY) gained. It was 
determined that the incidence of ovarian cancer at age 65 was significantly different for those 
that underwent prophylactic salpingectomy (2.2% incidence) versus those who did not receive 
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this operation (4.75% incidence). In addition, it was estimated that the salpingectomy would 
yield $23.9 million in dollars saved while having an ICER of $31,432/QALY compared to tubal 
ligation. (24)  
Finally, a meta-analysis conducted by Anggraeni et al., compiling five different studies 
examining the efficacy of salpingectomy conjectured that the risk of ovarian cancer for women 
of the general population would be reduced by 29.2%-64% (26). This was similar to the results 
of another meta-analysis by Yoon et al., that found a lower risk of incidence for ovarian cancer 
for patients who underwent bilateral salpingectomy compared to control (OR; 0.51, 95%CI 
0.35-0.75). (25) 
While the efficacy of this procedure is being established, the next question a physician should 
have in mind is whether or not to recommend this procedure to a patient seeking sterilization 
when contemplating the long-term safety profile. The major concerns that a physician must 
contend with regarding this procedure typically involve the effects of menopause on a woman’s 
cardiovascular, cerebrovascular, and bone health. There is well-established data that 
demonstrates the negative effect pre-menopausal oophorectomy has on these health factors as 
the protective effects of estrogen are removed. It has been demonstrated that there is an 
increased risk for mortality related to cardiovascular disease, strokes, and osteoporosis/hip 
fractures with pre-menopausal oophorectomy (15-16, 27-31). For example, current data has 
demonstrated that women older than sixty years of age with oophorectomy are at a twofold 
increase in mortality with hip fracture than compared to women with intact ovaries (29-30). 
The overall hope of leaving the ovaries intact and simply removing the fallopian tubes would be 
that long-term ovarian function would not be affected by this procedure.  
Since bilateral salpingectomies without oophorectomy have been performed only within the 
last decade, future studies should focus on a prospective cohort to measure the difference 
between individuals who receive tubal ligation and this procedure for morbidities and 
mortalities related to cardiovascular, cerebrovascular, and musculoskeletal pathologies. 
Current data supports the fact that risk-reducing salpingectomies do not affect ovarian function 
both at three months post-operatively as well as in a three to five-year follow-up (32). This data 
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is promising as it can be hypothesized that long-term complications will not arise; however, 
more prospective studies would be required before making an absolute argument in favor of 
ovarian preservation after bilateral salpingectomy.   
Another factor to consider before offering this procedure is understanding the cultural and 
religious beliefs that a woman may have. Despite the fact that this procedure is designed to 
prevent a horrible disease, it also may violate the ethical principles of people who practice 
religions such as Catholicism. This is an issue that should be brought to the spotlight as there is 
an estimated 51 million registered Catholics as of 2014 in the United States which comprise 
approximately 21% of the overall population (33).  
Although many Catholics are against the idea of contraception, the importance of living a full 
and healthy life is well-recognized by the Catholic Church. The Doctrine of Double Effect 
therefore plays a large role in this discussion where The New Catholic Encyclopedia states that 
this doctrine contains four conditions that must be met in order to consider an act, such as the 
bilateral salpingectomy, of moral high-ground: 1) the act itself must be morally good or at least 
indifferent, 2) the person may not consciously want the bad effect but may permit it, 3) the 
good effect must be produced directly from the act and not the bad effect, and 4) the good 
effect must compensate for allowing the bad effect. If pregnant, full-term Catholic mother and 
her husband are satisfied with the number of children they have and are hoping to use more 
effective means of preventing future pregnancies, a physician with the permission of their 
patient, should consult their religious authority to help patients feel more comfortable in 
following their faith while protecting themselves from deleterious disease.   
The next concern on the patient’s mind, as well as the hospital’s and insurance company are 
the cost of this procedure. The analysis revealed a significant difference between bilateral 
salpingectomy vs tubal ligation in terms of total charges the hospital billed the patient. There 
appeared to be a significant difference in charges depending on several factors including 
whether the hospital was urban (p<0.001), located in the west region (p<0.001), whether it was 
a teaching hospital (p<0.002), whether the patient was older (p<0.01), and the patient’s 
Charlson comorbidity score (p<0.01). We can conjecture that the older the patient as well as 
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the patients with higher comorbidity may be charged more based on the level of care billed for 
either for anesthesia or the surgeon. However, the other criteria are more subject to wide-
based interpretation and cannot be further delineated at this time. It is the hope that the total 
charges could be reduced for patients by initiating negotiation with hospital billing and 
insurance companies using the current data regarding the benefits of risk-reducing 
salpingectomy to make the procedure more affordable.  
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Conclusions 
The major focus of this paper, existing data, and future studies regarding the safety, cost, and 
efficacy of bilateral salpingectomy as prophylaxis against ovarian cancer is to address the 
concerns of four parties: patients, physicians, hospitals, and insurance companies.   
We want to provide patients ease of mind in knowing that this procedure is safe, simple, and 
cheap.  As physicians, we want to ensure that this procedure is not only feasible, but has 
proven long-term outcomes for ovarian cancer prophylaxis, and one that won’t increase 
morbidity or mortality. For hospitals and insurance companies, this procedure should be able to 
save them from having to pay for future costly medical expenses that revolve around first 
preventing unwanted pregnancies and secondly preventing the cost of having future 
hospitalizations due to complications of ovarian cancer.  
As of now, it appears that risk-reducing salpingectomy is relatively safe compared to its tubal 
ligation counterpart. However, the high cost of this procedure, which is most likely tied to 
hospital billing, should be closely examined in the hopes that negotiations can be set between 
hospitals and insurance companies to make the procedure more affordable for patients to pay 
in the short-term for ultimate long-term gain.  
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